View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
  2. Company News
January 15, 2019updated 12 Jul 2022 1:09pm

Daiichi Sankyo doses first patient in DESTINY-Breast04 trial

Daiichi Sankyo Company has dosed the first patient in the Phase III DESTINY-Breast04 trial that aims to investigate [fam-] trastuzumab deruxtecan for the treatment of patients with HER2 low, unresectable and / or metastatic breast cancer previously treated with one to two prior lines of chemotherapy.

Daiichi Sankyo Company has dosed the first patient in the Phase III DESTINY-Breast04 trial that aims to investigate [fam-] trastuzumab deruxtecan for the treatment of patients with HER2 low, unresectable and / or metastatic breast cancer previously treated with one to two prior lines of chemotherapy.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The trial is designed to compare [fam-] trastuzumab deruxtecan with the investigator’s choice of chemotherapies including capecitabine, eribulin, gemcitabine, paclitaxel, and nab-paclitaxel.

The global, randomised, active-controlled study intends to include up to 540 patients at around 160 sites in North America, Western Europe, Asia, and other regions.

Primary efficacy objective of the open-label, multicentre, two-arm trial is progression-free survival based on a blinded independent central review.

“DESTINY-Breast04 has been initiated based on preliminary Phase I study results to determine whether [fam-] trastuzumab deruxtecan could serve as a targeted therapy option.”

The trial’s safety objectives comprise serious adverse events, treatment-emergent adverse events and adverse events of special interest.

Its secondary efficacy goals are progression-free survival based on investigator assessment, overall survival, objective response rate and duration of response.

Daiichi Sankyo Oncology Research and Development DS-8201 Global Team Leader vice-president Gilles Gallant said: “DESTINY-Breast04 has been initiated based on preliminary Phase I study results to determine whether [fam-] trastuzumab deruxtecan could serve as a targeted therapy option for patients with HER2 low metastatic breast cancer that progresses after standard chemotherapy, regardless of HR status.

“HER2 targeting agents have improved survival rates for HER2 positive breast cancer, but none have been approved in HER2 low expressing tutors.

“DESTINY-Breast04, our third Phase III breast cancer trial with [fam-] trastuzumab deruxtecan, has potential to define a new patient population for HER2 targeted treatment.”

[Fam-] trastuzumab deruxtecan contains a humanised HER2 antibody attached to a new topoisomerase I inhibitor payload by a tetrapeptide-based linker.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena